Get a reply from this employer
Your resume and cover letter, tailored to exactly what they’re hiring for.
Nurix Therapeutics is seeking a Scientist 1 to join the Bioanalytical team in Brisbane, CA. You will develop and run LC-MS/MS assays for targeted protein degrader candidates, quantify drugs and metabolites, and report high-quality data to support in vivo and in vitro studies.
You will independently develop LC-MS/MS methods, troubleshoot equipment, and collaborate with pharmacology, chemistry and biology teams, contributing to drug discovery programs with rigorous data generation and
Help drive Nurix’s drug discovery programs by turning complex biological samples into the high-quality bioanalytical data that guides decisions. You will develop and run LC-MS/MS assays for targeted protein degrader candidates and work closely with pharmacology, chemistry and biology teams.
Nurix Therapeutics is searching for a motivated Scientist 1 to join our Bioanalytical team. The successful candidate will contribute to the bioanalytical efforts to support Nurix drug discovery programs involving in vivo and in vitro studies. The primary responsibility will be to conduct quantitative bioanalysis for in vivo samples. The scope of the daily responsibilities for this position includes, but is not limited to, developing bioanalytical methods, quantitating drug candidates and their metabolites, endogenous biomarkers in biological matrix (e.g. blood, plasma, tissues, tumor, CSF, etc.), and reporting high-quality data. The successful candidate will have extensive experience in bioanalytical method development and sample analysis using LC-MS/MS and other analytical techniques.
Onsite – Brisbane, CA
$141,500 - $175,600
The posted range applies to roles based in the San Francisco Bay Area and reflects local market conditions. Where an offer lands within that range depends on the candidate’s relevant experience, technical expertise, and how their background aligns with the role’s requirements.
Nurix Therapeutics is a clinical stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted protein degradation medicines, the next frontier in innovative drug design aimed at improving treatment options for patients with cancer and inflammatory diseases. Powered by a fully AI-integrated discovery engine capable of tackling any protein class, and coupled with unparalleled ligase expertise, Nurix’s dedicated team has built a formidable advantage in translating the science of targeted protein degradation into clinical advancements. Nurix aims to establish degrader-based treatments at the frontier of patient care, writing medicine’s next chapter with a new script to outmatch disease.